Richard M. Nixon
#189,663
Most Influential Person Now
Researcher
Richard M. Nixon's Degrees
- Bachelors History Whittier College
- Bachelors Law Duke University
Similar Degrees You Can Earn
Why Is Richard M. Nixon Influential?
(Suggest an Edit or Addition)Richard M. Nixon's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis (2015) (185)
- Non-parametric methods for cost-effectiveness analysis: the central limit theorem and the bootstrap compared. (2010) (165)
- The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. (2007) (143)
- Methods for incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations. (2005) (133)
- Developing Appropriate Methods for Cost-Effectiveness Analysis of Cluster Randomized Trials (2012) (132)
- The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. (2007) (108)
- Comment on: Modelling the cost effectiveness of TNF antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry (2008) (107)
- Parametric modelling of cost data in medical studies (2004) (103)
- Using mixed treatment comparisons and meta‐regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis (2007) (97)
- Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. (2008) (95)
- Parametric modelling of cost data: some simulation evidence. (2005) (94)
- Costs and quality of life of multiple sclerosis in the United Kingdom (2006) (92)
- Using multilevel models for assessing the variability of multinational resource use and cost data. (2005) (88)
- How Sensitive Are Cost-Effectiveness Analyses to Choice of Parametric Distributions? (2005) (88)
- No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis (2014) (86)
- Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. (2007) (84)
- Indicators of undernutrition in cattle (2006) (73)
- Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. (2007) (72)
- Randomised controlled trial of educational package on management of menorrhagia in primary care: the Anglia menorrhagia education study (1999) (59)
- Statistical Methods for Cost-Effectiveness Analyses That Use Data from Cluster Randomized Trials (2012) (53)
- Addressing the issues that arise in analysing multicentre cost data, with application to a multinational study. (2006) (53)
- Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population. (2009) (51)
- Bayesian Hierarchical Models for Cost-Effectiveness Analyses that Use Data from Cluster Randomized Trials (2010) (48)
- Methods for covariate adjustment in cost-effectiveness analysis that use cluster randomised trials. (2012) (48)
- A case study using the PrOACT‐URL and BRAT frameworks for structured benefit risk assessment (2016) (37)
- Meta-analysis of feeding trials investigating cadmium accumulation in the livers and kidneys of sheep. (2004) (37)
- Network meta-analysis combining individual patient and aggregate data from a mixture of study designs with an application to pulmonary arterial hypertension (2015) (36)
- Implications for the human food chain of models of cadmium accumulation in sheep. (2005) (35)
- The distribution of the cost of multiple sclerosis in the UK: how do costs vary by illness severity? (2007) (33)
- Multilevel models for cost-effectiveness analyses that use cluster randomised trial data: An approach to model choice (2016) (32)
- Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations (2002) (32)
- Multilevel models for estimating incremental net benefits in multinational studies. (2007) (32)
- Some random-effects models for the analysis of matched-cluster randomised trials: application to the Swedish two-county trial of breast-cancer screening. (2000) (24)
- A Bayesian approach to probabilistic sensitivity analysis in structured benefit‐risk assessment (2016) (23)
- Baseline adjustments for binary data in repeated cross‐sectional cluster randomized trials (2003) (23)
- Benefit–risk assessment in a post‐market setting: a case study integrating real‐life experience into benefit–risk methodology (2014) (22)
- Mammographic screening in women with a family history of breast cancer: some results from the Swedish two-county trial. (2000) (20)
- A comparison of clinical assessment with ultrasound in the management of secondary postpartum haemorrhage. (2002) (19)
- A meta-regression study aiming to evaluate frequently analysed metabolites as indicators of under-nutrition in cattle (2004) (17)
- High correlation of VAS pain scores after 2 and 6 weeks of treatment with VAS pain scores at 12 weeks in randomised controlled trials in rheumatoid arthritis and osteoarthritis: meta-analysis and implications (2016) (15)
- Initial results of a study into the effectiveness of breast cancer screening in a population identified to be at high risk. (2001) (12)
- Management of menorrhagia: an audit of practices in the Anglia menorrhagia education study (2001) (12)
- IMPACT OF LAND UTILIZATION SYSTEMS ON AGRICULTURAL PRODUCTIVITY (2003) (11)
- Efficacy and safety of diclofenac in osteoarthritis: Results of a network meta-analysis of unpublished legacy studies (2017) (11)
- Bayesian evaluation of breast cancer screening using data from two studies (2003) (10)
- Re: Hutchinson M, Fox RJ, Havrdova E, et al. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison. Curr Med Res Opin 2014;30:613-27 (2015) (10)
- Estimating the rates of disability progression in people with active relapsing-remitting multiple sclerosis (2007) (9)
- Randomization at the level of primary care practice: use of pre‐intervention data and random effects models (2001) (8)
- Using short‐term evidence to predict six‐month outcomes in clinical trials of signs and symptoms in rheumatoid arthritis (2009) (8)
- Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion (2014) (8)
- Imputation of a true endpoint from a surrogate: application to a cluster randomized controlled trial with partial information on the true endpoint (2003) (5)
- Cross-issue synthesis: potential application to breast cancer, tamoxifen and genetic susceptibility. (2002) (4)
- Indirect Comparisons of Oral Fingolimod Versus Natalizumab on Measures of Disease Freedom Based on Results from FREEDOMS and AFFIRM (P01.209) (2013) (2)
- Review and comparison of methodologies for indirect comparison of clinical trial results: an illustration with ranibizumab and aflibercept (2016) (2)
- Modeling the Impact of Disease Modifying Treatment on Time to Disability Health States in Multiple Sclerosis: An Evaluation of Oral Therapies Through Indirect Comparisons of 6-Month Confirmed Disability Progression (2013) (1)
- Using Decision Analysis to Support the Design of Clinical Trials Within a Program (2015) (1)
- Methods for covariate adjustment in cost-effectiveness analyses of cluster randomised trials (2011) (1)
- Covariate Adjustment and Subgroup Analysis in Cost-Effectiveness Evaluations (2007) (0)
- Better Reimbursement Decision-Making Based on Expected Cost-Effectiveness: Using Value of Information Decision Analysis to Improve The Design and Efficacy of A Phase Iii Program for Erlotinib. (2015) (0)
- studycare: the Anglia menorrhagia education package on management of menorrhagia in Randomised controlled trial of educational (2006) (0)
- THU0181 Association of VAS Pain Scale at Different Time Points in Rheumatoid Arthritis and Osteoarthritis Randomized Clinical Trials (2015) (0)
- PCV122 MODELING THE EFFECT OF DIFFERENTIAL COMPLIANCE WITH ANTIHYPERTENSIVE DRUGS ON CLINICAL ENDPOINTS (2008) (0)
- ANOXIC-AEROBIC STABILIZATION OF SETILED SEWAGE SLUDGE FROM A SEW AGE TREATMENT PLANT (2010) (0)
- Efficacy of Fingolimod in Delaying Confirmed Disability Progression in Patients Failing Prior Treatment: A Markov Model Application to Estimate Time to Disability Health States (2013) (0)
- Rehabilitation Medicine: Serving People With Disabilities (2007) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Richard M. Nixon?
Richard M. Nixon is affiliated with the following schools:
